Contact Information

Surgery


Uniformed Services University of the Health Sciences
Department of Surgery
4301 Jones Bridge Road
Bethesda, Maryland 20814
Phone: (301) 295-9843
Fax: (301) 295-1996
Email: shiva.srivastava@usuhs.edu

Patricia L. McKay, MD, MDCAPT, MC, USN
Interim Chairman

Dr. Norman M. Rich, MD,DMCC, FACS
Leonard Heaton-David Packard Professor
Chairman 1977 - 2002

Shiva Srivastava, Ph.D.

Professor, Surgery

Molecular Genetics of Prostate Cancer: Basic And Translational Research

The Basic Science Research Program (BSRP) of the CPDR is a multi-disciplinary program that integrates the research efforts of cancer molecular and cell biologists, urologists, genitourinary pathologist and medical informatics expertise. A full time staff including the Scientific Director, an Associate Director, an Assistant Director, Senior Staff Scientists, Staff Scientists, Post-doctoral Fellows, Urology Residents, PhD Students, Lab Manager and Grants Specialist support the activities of the BSRP. Objectives of our current research are to address molecular and cellular mechanisms of prostate tumorigenesis and to develop diagnostic and prognostic markers for prostate cancer. Current research efforts include:

  • Molecular genetic alterations in prostate cancer with focus on Tumor Suppressor Genes (TSGs): (p53, p63, p16, p27, positional cloning of novel TSG on 6q16 locus)
  • Role of androgen signaling net-work in prostate cancer; Evaluation of the androgen regulated transcriptome in prostate cancer cells by high-throughput expression strategies of SAGE and GeneChips; Development of the Androgen Signaling Reporter Array (ASRA) for prostate cancer; A novel mechanism of feed-back regulation of the androgen receptor (AR) by PMEPA1 gene discovered at CPDR.
  • Discovery of novel prostate specific genes (PCGEM1, PSGR, PMEPA1, NKX3.1): Biology and translational utility.
  • Delineation of novel prostate cancer specific alterations by genomics and proteomics: molecular markers of prostate cancer onset and/or progression.
  • Functional analysis of most common prostate cancer gene alterations: HEPSIN, AMACR.
  • Diagnostic and prognostic utility of the Circulating PSA Expressing Cells (CPECs) in blood.
  • Developing novel serum markers for prostate cancer: complex proteomics profiles defined by mass spectrometry and other high through-put platforms.
  • Development of novel cell culture models.